同源康医药-B(02410.HK)：甲磺酸艾多替尼片“TY-9591片”被药监局药品审评中心纳入优先审评品种名单

Core Viewpoint - The company Tongyuan Kang Pharmaceutical-B (02410.HK) announced that its investigational first-class new drug, Tyrosine Kinase Inhibitor (TY-9591), has been included in the priority review list by the National Medical Products Administration (NMPA) [1] Group 1 - The application for TY-9591 meets the requirements of the "Drug Registration Management Measures" and the announcement regarding the "Procedures for the Review of Breakthrough Therapy Drugs" [1] - The drug has been accepted into the priority review process under the category of "drugs eligible for conditional approval" [1]